engineered sirp alpha variants immunotherapeutic adjuvants anticancer antibodies
cd47 antiphagocytic signal cancer cells employ inhibit macrophage-mediated destruction modified binding domain human sirp alpha receptor cd47 use cd47 antagonist engineered high-affinity sirp alpha variants -fold increased affinity human cd47 relative wild-type sirp alpha high-affinity sirp alpha monomers potently antagonized cd47 cancer cells induce macrophage phagocytosis instead exhibited remarkable synergy tumor-specific monoclonal antibodies tested increasing phagocytosis vitro enhancing antitumor responses vivo one-two punch directs immune responses tumor cells lowering threshold macrophage activation thereby providing universal method augmenting efficacy therapeutic anticancer antibodies
